BACKGROUND: Debates about cannabis policy often mention respiratory symptoms as a negative consequence of use. The cannabis vaporizer, a machine that heats the plant to release cannabinoids in a mist without smoke and other respiratory irritants, appears to have the potential to minimize respiratory complaints. METHODS:Twenty frequent cannabis users (uninterested in treatment) reporting at least two respiratory symptoms completedsubjective ratings of respiratory symptoms and spirometry measures prior to and following 1 month's use of a cannabis vaporizer in a pre/post-design. Outcome measures included self-reported severity of nine respiratory symptoms as well as spirometry measures, including the maximum amount of air exhaled in 1s (forced expiratory volume; FEV1) and maximum total lung volume (forced vital capacity; FVC). RESULTS: The 12 participants who did not develop a respiratory illness during the trial significantly improved respiratory symptoms (t(11)=6.22, p=0.000065, d=3.75) and FVC, t(11)=2.90, p=0.007, d=1.75. FEV1 improved but not significantly t(11)=1.77, p=0.053, d=1.07. CONCLUSIONS: These preliminary data reveal meaningful improvements in respiratory function, suggesting that a randomized clinical trial of the cannabis vaporizer is warranted. The vaporizer has potential for the administration of medical cannabis and as a harm reduction technique.
RCT Entities:
BACKGROUND: Debates about cannabis policy often mention respiratory symptoms as a negative consequence of use. The cannabis vaporizer, a machine that heats the plant to release cannabinoids in a mist without smoke and other respiratory irritants, appears to have the potential to minimize respiratory complaints. METHODS: Twenty frequent cannabis users (uninterested in treatment) reporting at least two respiratory symptoms completed subjective ratings of respiratory symptoms and spirometry measures prior to and following 1 month's use of a cannabis vaporizer in a pre/post-design. Outcome measures included self-reported severity of nine respiratory symptoms as well as spirometry measures, including the maximum amount of air exhaled in 1s (forced expiratory volume; FEV1) and maximum total lung volume (forced vital capacity; FVC). RESULTS: The 12 participants who did not develop a respiratory illness during the trial significantly improved respiratory symptoms (t(11)=6.22, p=0.000065, d=3.75) and FVC, t(11)=2.90, p=0.007, d=1.75. FEV1 improved but not significantly t(11)=1.77, p=0.053, d=1.07. CONCLUSIONS: These preliminary data reveal meaningful improvements in respiratory function, suggesting that a randomized clinical trial of the cannabis vaporizer is warranted. The vaporizer has potential for the administration of medical cannabis and as a harm reduction technique.
Authors: Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room Journal: Am J Public Health Date: 2017-06-23 Impact factor: 9.308
Authors: Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain Journal: Drug Alcohol Depend Date: 2020-04-26 Impact factor: 4.492
Authors: Jacob T Borodovsky; Dustin C Lee; Benjamin S Crosier; Joy L Gabrielli; James D Sargent; Alan J Budney Journal: Drug Alcohol Depend Date: 2017-06-09 Impact factor: 4.492
Authors: S Grassin-Delyle; E Naline; A Buenestado; C Faisy; J-C Alvarez; H Salvator; C Abrial; C Advenier; L Zemoura; P Devillier Journal: Br J Pharmacol Date: 2014-06 Impact factor: 8.739
Authors: Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; David A Gorelick; Gary Gaffney; Marilyn A Huestis Journal: Drug Test Anal Date: 2015-08-10 Impact factor: 3.345